Tecentriq Demonstrates Survival Benefit in ctDNA-Guided Bladder Cancer Treatment at ESMO 2025

Tecentriq; atezolizumab; ctDNA-guided therapy; IMvigor011; bladder cancer; muscle-invasive bladder cancer; adjuvant treatment; overall survival; disease-free survival; ESMO 2025; Signatera; Genentech; Roche

Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium

Natera; ESMO Congress; IMvigor011 trial; Presidential Symposium; Signatera; molecular residual disease; muscle-invasive bladder cancer; adjuvant Tecentriq; precision medicine; clinical oncology

Continuous Bioprocessing for Bispecific Antibodies: Innovations Accelerating Therapeutic Antibody Production (2024–2025)

continuous bioprocessing; bispecific antibodies; therapeutic antibody production; bioprocess innovation; high-throughput production; antibody engineering; scale-up; oncology therapeutics; protein purification; automation

Trump Administration Launches Tariff Probe into Medtech and Pharmaceutical Industries

Trump administration; tariffs; medtech industry; pharmaceutical imports; Section 232 investigation; semiconductor tariffs; national security; supply chain; manufacturing; medical devices

Lilly’s Mounjaro Shows Strong Results in Youth Type 2 Diabetes, Paving Way for Expansion

Mounjaro; tirzepatide; type 2 diabetes; children; adolescents; SURPASS-PEDS; A1C reduction; BMI reduction; clinical trial; Eli Lilly

Trump Administration May Exempt Some Pharma Products from Future Tariffs in Trade Policy Shift

pharmaceutical tariffs; tariff exemptions; Trump administration; Section 232 investigation; trade policy; reciprocal tariffs; generic pharmaceuticals; active pharmaceutical ingredients; commerce secretary authority